Cancer programs seek to remove barriers to screenings.
Cancer deaths are expected to increase over the next decade due to screening deficits caused by the COVID-19 pandemic, according to new research.
Around the nation, 748 accredited cancer programs reported decreases in screenings for colorectal (80.6%), cervical (69%), breast (55.3%) and lung cancer (44.6%), according to a study initiated by the American College of Surgeons Cancer Programs and the American Cancer Society.
The results were announced by Wiley and published in Cancer, the journal of the American Cancer Society.
“From the perspective of people’s health, we are hopeful that this collaborative effort between the American College of Surgeons Cancer Programs and the American Cancer Society may have saved many patients from unnecessary suffering and death from cancer,” co-author Heidi Nelson, MD, FACS, said in a news release.
The study period took place from April 2021 through June 2021.
Using the results, the participating cancer programs initiated 814 quality improvement projects to address various barriers to screening, and are assessing the effects of those interventions.
If all participating facilities reach their target goals, the estimated numbers of potential additional monthly screening tests are:
“From the perspective of what this means about our programs, we now know that we can turn to our accredited programs in times of crisis to help address large-scale cancer problems,” said Nelson, who is medical director of cancer programs at the American College of Surgeons. “Knowing how enthusiastic these accredited programs are for working collaboratively on national level problems, we expect to release one or two quality improvement projects each year going forward.”
Researchers did not see geographic differences based on the locations of cancer programs across the United States.
The researchers said the study was timely because the American Cancer Society's National Consortium for Cancer Screening and Care recently announced nine consensus recommendations to accelerate recovery from the pandemic and improve the nation's ability to provide quality cancer screening and care for all.
This article was originally published on Medical Economics®.
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
February 21st 2024A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More